

PHARMACEUTICAL 2023

CORCEPT THERAPEUTICS INC Rank 12 of 446









RealRate

PHARMACEUTICAL 2023

CORCEPT THERAPEUTICS INC Rank 12 of 446



The relative strengths and weaknesses of CORCEPT THERAPEUTICS INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of CORCEPT THERAPEUTICS INC compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 123% points. The greatest weakness of CORCEPT THERAPEUTICS INC is the variable Intangible Assets, reducing the Economic Capital Ratio by 3.1% points.

The company's Economic Capital Ratio, given in the ranking table, is 290%, being 247% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	499,253
Cost of Goods Sold	5,385
Intangible Assets	0
Liabilities, Current	72,491
Liabilities, Non-Current	0
Other Assets	83,544
Other Compr. Net Income	-642
Other Expenses	14,773
Other Liabilities	9,097
Other Net Income	3,557
Other Revenues	401,858
Property and Equipment	633
Research and Development	130,991
Selling, General and Administrative Expense	152,848

Output Variable	Value in 1000 USD
Assets	583,430
Liabilities	81,588
Expenses	303,997
Revenues	401,858
Stockholders Equity	501,842
Net Income	101,418
Comprehensive Net Income	101,097
Economic Capital Ratio	290%

